GlassScriptPhysician profile
Thomas P Allen
NPI 1801854294
$10,480.78
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,915 · 2020: $1,163 · 2021: $2,883 · 2022: $2,428 · 2023: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,091.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,366.65 | 2019-2023 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $1,104.83 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $992.71 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $788.16 | 2019-2023 | Prolia, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $636.73 | 2019-2023 | Farxiga, Fasenra |
| Merck Sharp & Dohme LLC | $539.41 | 2019-2023 | Belsomra, Steglatro, Lagevrio |
| Abbott Laboratories | $490.79 | 2021-2023 | Freestyle Libre 3, Proclaim, Eterna |
| Amarin Pharma, INC. | $434.56 | 2019-2022 | |
| Pfizer INC. | $422.76 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $346.40 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $301.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.84 | 2019-2023 | Synjardy, Tradjenta, Jardiance |
| Sanofi-Aventis U.S. LLC | $234.66 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.20 | 2021-2023 | |
| Mylan Specialty L.P. | $161.02 | 2020-2023 | Yupelri |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.